Ikarian Capital’s RAPT Therapeutics RAPT Stock Holding History

Ikarian Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-290,000	Closed	-$9.82M	–	203
2025 Q4	$9.82M	Buy	290,000 +115,000	+66%	+$3.57M	0.77%	36
2025 Q3	$4.51M	Buy	+175,000	New	+$2.29M	0.46%	55
2024 Q3	–	Sell	-250	Closed	-$610K	–	168
2024 Q2	$610K	Sell	250 -10,650	-98%	-$492K	0.11%	90
2024 Q1	$783K	Buy	+10,900	New	+$1.52M	0.09%	111
2021 Q2	–	Sell	-31,250	Closed	-$5.55M	–	267
2021 Q1	$5.55M	Buy	31,250 +30,812	+7,035%	+$5.08M	0.19%	112
2020 Q4	$69K	Sell	438 -225	-34%	-$48.9K	﹤0.01%	219
2020 Q3	$170K	Buy	+663	New	+$147K	0.01%	161

Ikarian Capital's RAPT Position: Q1 2026 in Review

Ikarian Capital sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 665,271 shares — an estimated $22.5M sold.

Ikarian Capital first reported a position in RAPT in Q1 2024 and held it in 5 quarters. The position peaked at $22.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

Ikarian Capital reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
Ikarian Capital sold 665,271 RAPT Therapeutics shares in Q1 2026, an estimated $22.5M.
Ikarian Capital first reported a position in RAPT Therapeutics in Q1 2024 and held it in 5 quarters.
Ikarian Capital's RAPT Therapeutics position peaked at $22.5M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.